Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 9/20 | 0.41 |
| ▸ | ESR1 | P03372 | 8/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CA6 | P23280 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802016 | 0.72 | MAOB (0.48) | ESR2ESR1MAOBMAOACES2 | |
| SCHEMBL6800031 | 0.72 | MAOB (0.48) | ESR2ESR1MAOBMAOACES2 | |
| SCHEMBL6794708 | 0.71 | PBRM1 (0.46) | ESR2ESR1MAOBMAOAPBRM1 | |
| SCHEMBL6794055 | 0.70 | ESR1 (0.44) | ESR2ESR1MAOBMAOAPBRM1 | |
| SCHEMBL6800771 | 0.68 | ESR2 (0.35) | ESR2ESR1MAOB | |
| SCHEMBL6794599 | 0.68 | ESR2 (0.49) | ESR2ESR1CA1CA2CA4 | |
| SCHEMBL6802316 | 0.68 | MIF (0.46) | ESR2ESR1MAOBMAOA | |
| SCHEMBL6797976 | 0.66 | MAOB (0.46) | MAOBMAOACES2 | |
| SCHEMBL6796287 | 0.66 | MAOB (0.46) | MAOBMAOACES2 | |
| SCHEMBL6799659 | 0.65 | DRD2 (0.45) | ESR2ESR1PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | MERCK & CO., INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | ESRRA, ESRRB, FSHR | ESR2 5/4885ESR1 19/4885MAOB 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.